NEW HAVEN, Conn., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
(Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a
corporate overview at the 25th Annual Credit Suisse Healthcare Conference on Monday, November 7, 2016 at 1:00 p.m. MT at
The Phoenician Hotel in Scottsdale, AZ.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the
Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live
presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time
for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage
its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with
serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue
best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement
inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing
life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 gschulman@achillion.com Media: Liz Power Achillion Pharmaceuticals, Inc. Tel: (203) 752-5509 lpower@achillion.com
